ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Catheter Precision (VTAK)
Catheter Precision stock price today, ATLAS forecast and fair value
Healthcare · Medical Devices · NYSE
$0.65▼ -8.45%
Prices as of Oct 26, 2026 · USD
Chance of rising in 1 month
39%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Catheter Precision in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Catheter Precision
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Catheter Precision a 39% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $0.42 and $0.78; in 9 out of 10, between $0.24 and $1.35. Estimated annual volatility is 200%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $0.3M
- 52-week high
- $6.40
- 52-week low
- $0.55
- Revenue (12 months)
- $1.9M
- Revenue growth (YoY)
- +95.0%
- Gross margin
- 92.3%
- Return on equity
- -111.4%
- Free cash flow (12 months)
- $-4.4M
- Beta
- 0.47
What this means
ATLAS does not publish a fair value for VTAK right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks VTAK has traded between $0.55 and $6.40. Today it is 89.8% below that high and 18% above its low.
Its beta is 0.47: it tends to move less than the market.
About the company
Catheter Precision Inc. is a medical device company focused on cardiac electrophysiology, developing technologies used by clinicians to evaluate and treat abnormal heart rhythms.
Want to see everything about Catheter Precision?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Catheter Precision do?
Catheter Precision Inc. is a medical device company focused on cardiac electrophysiology, developing technologies used by clinicians to evaluate and treat abnormal heart rhythms.
What is the chance VTAK goes up next month?
39%: somewhat worse than a coin flip. In half of the simulated outcomes, VTAK ends the month between $0.42 and $0.78.
How big is Catheter Precision and what is its P/E ratio?
Catheter Precision's market capitalization is $0.3M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is VTAK?
ATLAS estimates annual volatility at 200%. In a typical month, half of the outcomes end between $0.42 and $0.78.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer